Print Email

About Study Groups  |  Study Groups  |  Workshops  |  Surveys  |  Resources

MASCC Neutropenia, Infection & Myelosuppression Study Group

Leadership

Chair: Jean Klastersky, MD (jean.klastersky@bordet.be) - Belgium
Vice-Chair: Bernardo Rapaport, MD (
brapoport@icon.co.za) - South Africa

2017 Workshop

2017 Annual Meeting Workshop, June 22, Washington, DC
How Adherence to Guidelines Increases the Cost-Effectiveness of Supportive Care Interventions
The need to increase the cost-effectiveness of medical treatments is recognized around the globe. One way to increase cost-effectiveness is by following evidence-based guidelines that consider cost containment. This workshop is intended to provide evidence for the need to adhere to such guidelines, both to improve outcomes and to ensure that available resources are used in the most appropriate manner. We will review current guidelines from this perspective and note possible negative consequences of non-adherence. We will also highlight the importance of a multidisciplinary approach to cancer treatment and supportive care. 

This workshop will be offered jointly by the following MASCC Study Groups: Antiemetics; Neutropenia, Infection, and Myelosuppression; Oral Care;  Psychosocial.
Workshop Chair: Bernardo Rapoport

Past Workshops

Research Highlights

Identifying Patients at Low Risk for FN Complications: Development and Validation of the MASCC Risk Index Score
Febrile neutropenia (FN) is a life-threatening complication of cancer chemotherapy and is considered a medical emergency. The classic treatment strategy has been broad-spectrum antibiotics administered intravenously in a hospital setting, and most patients respond promptly with no complications. For more than 20 years, Jean Klastersky and colleagues have worked on the development and testing of a reliable tool for identifying patients at low risk for complications of FN. The resulting MASCC Risk Index Score makes it possible to identify patients who can safely be treated at home. This work began with a 1994 survey to identify independent predictive factors that could be assessed at fever onset in adult febrile neutropenic cancer patients being treated with chemotherapy. The resulting Risk Index Score has now seen more than 10 years of use and has proven to be a reliable and valuable tool to identify low risk patients. Read More >>

Clinical App

Calculate by QxMD - (Free) Calculate the MASCC Febrile Neutropenia score in addition to included tools which are useful in clinical practice and serve to impact diagnosis, treatment or determining prognosis.

Guidelines MASCC-Endorsed Practice Guidelines


International Pediatric Fever and Neutropenia Guideline
  
From The Hospital for Sick Children (SickKids.ca)
Fever and neutropenia (FN) is a common complication in children who receive chemotherapy for cancer. The Study Group convened a panel of pediatric cancer and infectious diseases experts to develop an evidence-based guideline for the empiric management of pediatric FN. This guideline focuses on children and adolescents with cancer, or who are undergoing hematopoietic stem cell transplantation, and who have FN. The guideline is designed for healthcare professionals who care for these patients. Implementation requires adaptation to the local context and consideration of organizational barriers, such as the availability of a local infrastructure, to support different models of care.

Publications

Georgala A, Klastersky JA. Prophylaxis of febrile neutropenia in adults receiving chemotherapy needs to be adapted to the risk. Expert Rev Hematol. 2015 Feb;8(1):115-21.

Klastersky J, Georgala A. Strategies for the empirical management of infection in cancer patients with emphasis on the emergence of resistant gram-negative bacteria. Crit Rev Oncol Hematol. 2014 Dec;92(3):268-78.

Klastersky JA. Supportive care is a constant state of changing: we need to adjust for it. Curr Opin Oncol. 2014 Jul;26(4):371.

Klastersky JA. Adverse events of targeted therapies. Curr Opin Oncol. 2014 Jul;26(4):395-402.

Klastersky JA. Supportive care in cancer patients: a unifying concept. Curr Opin Oncol. 2013 Jul;25(4):341.

Klastersky J, Raftopoulos H, Rapoport B. The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia. Support Care Cancer. 2013 Jun;21(6):1793-5.

Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer. 2013 May;21(5):1487-95.

Aapro MS, Bholius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al.; for the European Organisation for Research and Treatment of Cancer. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011 Jan;47(1):8-32.

Rapoport BL. Management of the cancer patient with infection and neutropenia. Semin Oncol. 2011 Jun;38(3):424-30.


Please contact the Study Group Chairs above with your questions.
MASCC Study Group Coordinator, Don Gubitosa